Brexanolone clinical trials

Pro Research Analysisby

Searched over 200M research papers

Analyzed relevant papers

Brexanolone Clinical Trials: Efficacy and Safety in Postpartum Depression

Brexanolone for Postpartum Depression: Clinical Trial Overview

Brexanolone is the first medication specifically approved for the treatment of postpartum depression (PPD) in the United States, following a series of clinical trials that demonstrated its effectiveness and safety in women with moderate to severe PPD Epperson2022Gerbasi2020Walkery2021+3 MORE. The drug is an intravenous formulation of allopregnanolone, a neuroactive steroid that modulates GABA-A receptors, which are believed to play a role in mood regulation Kanes2017Walkery2021Patatanian2020+1 MORE.

Efficacy Results from Phase 2 and Phase 3 Trials

Multiple randomized, double-blind, placebo-controlled trials have shown that brexanolone leads to rapid and significant reductions in depressive symptoms, as measured by the Hamilton Rating Scale for Depression (HAM-D) Meltzer-Brody2018Kanes2017Epperson2022+7 MORE. In these studies, women receiving brexanolone experienced greater improvements in HAM-D scores compared to placebo, with effects seen as early as 24 hours and sustained through at least 30 days after infusion Meltzer-Brody2018Kanes2017Epperson2022+3 MORE. Pooled analyses from three major trials found that brexanolone-treated patients had higher response and remission rates, and achieved symptom improvement more quickly than those receiving placebo Epperson2022Gerbasi2020Zheng2019+1 MORE.

Safety and Tolerability of Brexanolone

Brexanolone was generally well tolerated in clinical trials. The most common side effects included headache, dizziness, somnolence (sleepiness), and, less frequently, excessive sedation or loss of consciousness Meltzer-Brody2018Kanes2017Walkery2021+3 MORE. Serious adverse events were rare, but due to the risk of excessive sedation, continuous monitoring is recommended during the 60-hour intravenous infusion Meltzer-Brody2018Kanes2017Leader2019+1 MORE. Discontinuation rates due to adverse events were similar between brexanolone and placebo groups, though overall discontinuation for any reason was higher with brexanolone .

Clinical Impact and Practical Considerations

Brexanolone offers a novel, fast-acting treatment option for women with moderate to severe PPD, with rapid onset of action and sustained benefits Meltzer-Brody2018Kanes2017Epperson2022+7 MORE. However, its use is limited by the need for a prolonged intravenous infusion in a monitored healthcare setting, high cost, and restricted access due to safety monitoring requirements Walkery2021Leader2019Patatanian2020+1 MORE. Despite these challenges, brexanolone represents a significant advancement in the management of PPD, providing meaningful and lasting symptom relief for many women Epperson2022Gerbasi2020Walkery2021+5 MORE.

Conclusion

Clinical trials consistently show that brexanolone is an effective and generally safe treatment for postpartum depression, offering rapid and sustained improvement in depressive symptoms. While logistical and safety considerations may limit its widespread use, brexanolone marks an important step forward in addressing the urgent need for targeted therapies in PPD.

Sources and full results

Most relevant research papers on this topic

Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials.

Brexanolone injection effectively reduces moderate to severe post-partum depression in women, but may cause serious adverse events.

RCTLarge Human TrialRigorous JournalHighly Cited

2018·

459citations

·S. Meltzer-Brody et al.

Lancet·

DOI

Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial.

Brexanolone infusion significantly reduced the Hamilton Rating Scale for Depression total score in women with severe post-partum depression compared to placebo.

RCTRigorous JournalHighly Cited

2017·

348citations

·S. Kanes et al.

Lancet·

DOI

Effect of brexanolone on depressive symptoms, anxiety, and insomnia in women with postpartum depression: Pooled analyses from 3 double-blind, randomized, placebo-controlled clinical trials in the HUMMINGBIRD clinical program.

Brexanolone rapidly improves depressive symptoms, anxiety, and insomnia in women with postpartum depression compared to placebo.

RCTRigorous Journal

2022·

63citations

·C. Epperson et al.

Journal of affective disorders·

DOI

Brexanolone in Postpartum Depression: Post Hoc Analyses to Help Inform Clinical Decision-Making

Brexanolone injection provides meaningful changes, rapid and sustained improvements in postpartum depression symptoms, with low number needed to treat and large number needed to harm values.

Meta-Analysis

2020·

21citations

·M. Gerbasi et al.

Journal of Women's Health·

DOI

Review of Allopregnanolone Agonist Therapy for the Treatment of Depressive Disorders

Allopregnanolone agonists show potential in reducing depression scores, particularly in postpartum depression, major depressive disorder, and bipolar disorder.

Systematic ReviewRigorous Journal

2021·

38citations

·Autumn Walkery et al.

Drug Design, Development and Therapy·

DOI

Brexanolone for Postpartum Depression: Clinical Evidence and Practical Considerations

Brexanolone significantly reduces depression scores in women with moderate to severe postpartum depression, but a REMS program is needed to mitigate adverse events.

Systematic Review

2019·

35citations

·Lauren D. Leader et al.

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy·

DOI

Brexanolone: A Novel Drug for the Treatment of Postpartum Depression

Brexanolone is a safe and effective treatment for moderate to severe postpartum depression, but high costs, serious adverse effects, and restricted access may limit its use in clinical practice.

Systematic Review

2020·

24citations

·E. Patatanian et al.

Journal of Pharmacy Practice·

DOI

Novel neurosteroid therapeutics for post-partum depression: perspectives on clinical trials, program development, active research, and future directions

Brexanolone, a rapidly acting antidepressant, and other neurosteroids like zuranolone and ganaxolone show promise in treating postpartum depression and improving understanding of depressive disorders.

2023·

60citations

·R. Patterson et al.

Neuropsychopharmacology·

DOI

Brexanolone for postpartum depression: A meta-analysis of randomized controlled studies.

Brexanolone infusion has a rapid antidepressant effect for postpartum depression, lasting up to 1 week, but its long-term therapeutic effect needs further large-scale randomized controlled trials.

Meta-AnalysisRigorous Journal

2019·

51citations

·Wei Zheng et al.

Psychiatry research·

DOI

The efficacy and safety of some new GABAkines for treatment of depression: A systematic review and meta-analysis from randomized controlled trials.

Brexanolone and zuranolone show potential in improving depression symptoms in patients with major depressive disorder and postpartum depression, but may cause more adverse events in MDD patients.

Meta-Analysis

2023·

13citations

·Jiao Zou et al.

Psychiatry research·

DOI

Try another search

duration of action of calcium carbonate as an antacid

atmospheric composition of outer space

treatment options for chronic urticaria

Trends in digital mental health interventions and their effectiveness

undiscovered subatomic particles

Simplification methods for complex equations in applied mathematics